BR PR LG COR LMA MEL BL UT LEU REN PAN OV MES CNS BR 88 12 BR PR 89 11 PR LG 12 75 13 LG COR 40 40 20 CO LMA 100 LY MEL 100 ME BL 86 14 BL UT 100 UT LEU 100 LE REN 17 16 67 RE PAN 20 60 20 PA OV 30 30 30 OV MES 25 75 MS CNS 100 CS BR PR LG COR LMA MEL BL UT LEU REN PAN OV MES CNS

^a BR, breast adenocarcinoma (n = 11, 3); PR, prostate adenocarcinoma (n = 10, 1); LG, lung adenocarcinoma (n = 11, 3); COR, colorectal adenocarcinoma (n = 11, 6); LMA, lymphoma (n = 22, 0); MEL, melanoma (n = 10, 2); BL, bladder cell transitional carcinoma (n = 11, 4); UT, uterine adenocarcinoma (n = 10, 2); LEU, leukemia (n = 30, 0); REN, renal cell adenocarcinoma (n = 11, 5); PAN, pancreatic adenocarcinoma (n = 11, 6); OV, ovarian adenocarcinoma (n = 11, 8); MES, pleural mesothelioma (n = 11, 3); CNS (n = 20, 0). Numbers in parentheses refer to the total number of tissues samples in each tumor class and the number of unclassifiable tissues in each class, respectively.

Return to article